血管加压素生物标志物和肽素与全身炎症相关并优化失代偿期肝硬化的预后评估
在维也纳肝硬化研究(NCT03267615)中前瞻性纳入475例晚期慢性肝病(ACLD)患者,按6个预设临床阶段分类。在失代偿期ACLD(dACLD)患者中开发MELD-和肽素评分,并在内部验证队列(n=148)和外部验证队列(n=771)中验证。和肽素与白介素-6独立相关,MELD-和肽素评分对肝脏相关事件的AUROC高于MELD-Na评分。
要点
- 和肽素水平随ACLD严重程度进展而升高:S0为7.5 pmol/L vs S5为14.3 pmol/L(P<.001)。
- 在dACLD中,和肽素与白介素-6水平独立相关(校正Beta=0.10,P<.001)。
- MELD-和肽素评分在内部验证队列中预测6个月肝脏相关死亡的AUROC为0.777,高于MELD-Na的0.673。
核心结论
- 在dACLD患者中,和肽素与全身炎症独立相关。
- MELD-和肽素评分可识别dACLD中临床结局不良风险较高的患者。
研究设计与样本
- 维也纳肝硬化研究(NCT03267615)前瞻性纳入2017年1月至2023年4月间有和肽素水平的ACLD患者,按6个预设临床阶段(S0至S5)分类。
- 在dACLD患者中开发MELD-和肽素评分,推导队列n=150,内部验证队列n=148,外部验证队列n=771。
主要发现
- 共纳入475例ACLD患者,其中代偿期177例,失代偿期298例。
- 和肽素中位水平随ACLD严重程度进展而升高:S0为7.5 pmol/L vs S5为14.3 pmol/L(P<.001)。
- 在dACLD中,和肽素与白介素-6水平独立相关(校正Beta=0.10,P<.001)。
- 在dACLD中,和肽素与进一步失代偿风险相关(校正亚分布风险比=1.01,95%CI 1.00-1.01,P=.039)。
- 在dACLD中,和肽素与慢加急性肝衰竭风险相关(校正亚分布风险比=1.01,95%CI 1.01-1.02,P<.001),并与肝脏相关死亡风险相关(校正亚分布风险比=1.01,95%CI 1.01-1.02,P<.001),独立于相关协变量。
关键数值与推荐
- 在内部验证队列中,MELD-和肽素评分预测6个月肝脏相关死亡的AUROC为0.777,MELD-Na评分为0.673。
- 在内部验证队列中,MELD-和肽素评分预测1年肝脏相关死亡的AUROC为0.784,MELD-Na评分为0.661。
- 在内部验证队列中,MELD-和肽素评分预测2年随访肝脏相关死亡的AUROC为0.741,MELD-Na评分为0.636。
- 在外部验证队列中,MELD-和肽素评分在3、6、12个月随访时对肝脏相关死亡和慢加急性肝衰竭发生的AUROC均高于MELD-Na评分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Copeptin, an arginine-vasopressin biomarker, may confer prognostic information in patients with advanced chronic liver disease (ACLD). METHODS: Patients with ACLD included in the Vienna Cirrhosis Study (NCT03267615) between January 2017 and April 2023 and available copeptin levels were prospectively recruited and classified into 6 predefined clinical ACLD stages from S0 (subclinical portal hypertension) to S5 (further decompensation). A prognostic score (MELD-copeptin score) in patients with decompensated ACLD (dACLD) was developed in a derivation cohort (n = 150) and validated in an internal (n = 148) and an external validation cohort (n = 771). RESULTS: Among 475 patients with ACLD, 177 were compensated, whereas 298 were decompensated. Median levels of copeptin increased with progressive ACLD severity (S0, 7.5 pmol/L vs S5, 14.3 pmol/L; P < .001). Copeptin (adjusted Beta, 0.10; P < .001) was independently associated with interleukin-6 levels in dACLD. In dACLD, copeptin was linked to higher risk of further decompensation (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.00-1.01; P = .039), acute-on-chronic liver failure (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.01-1.02; P < .001), and liver-related death (adjusted subdistribution hazard ratio, 1.01; 95% confidence interval, 1.01-1.02; P < .001) independently of relevant cofactors. The MELD-copeptin score yielded higher area under the receiver operating characteristics (AUROCs) for liver-related events than the MELD-Na score in the internal validation cohort, accurately predicting liver-related death at 6 months (AUROC, 0.777 vs MELD-Na, 0.673), 1 year (AUROC, 0.784 vs MELD-Na, 0.661), and 2 years of follow-up (AUROC, 0.741 vs MELD-Na, 0.636). Similarly, the MELD-copeptin score consistently yielded higher AUROCS for the development of liver-related death and acute-on-chronic liver failure at 3, 6, and 12 months of follow-up in the external validation cohort. CONCLUSIONS: In patients with dACLD, copeptin is independently linked to systemic inflammation. The MELD-copeptin score identifies patients with dACLD at risk for impaired clinical outcomes.
引用
- Hartl L, Hintersteininger M, Simbrunner B, et al. The Vasopressin Biomarker Copeptin Is Linked to Systemic Inflammation and Refines Prognostication in Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2025. PMID: 40467020. doi:10.1016/j.cgh.2025.04.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。